Abstract:1,4-dihydropyrimidine-2-thiones were synthesized in five series that include 5-carboxylic acid derivatives of dihydropyrimidine (series A, 6 – 8 ), novel 5-carboxamide derivatives of dihydropyrimidine (series B, 9 – 14 ), N,S - dimethyl - dihydropyrimidine (series C, 15 – 20) , N -hydrazinyl derivatives of dihydropyrimidine (series D, 21 – 24) and tetrazolo dihydropyrimidine derivatives (series E, 25 – 28 ), and evaluated for anti-diabetic capability. The prepared novel compounds were structurally established by FTIR, 1 HNMR, 13 CNMR, ESI and HRMS. All of these compounds from series A - E were first time examined for α-glucosidase inhibition as to evaluate their anti-diabetic potential. Most of the compounds for example 8, 11 – 14, 15, 17 – 21, 25 and 28 demonstrated greater α-glucosidase inhibitory effects (IC 50 = 12.5 ± 0.21 to 47.3 ± 0.23 μM) when compared to deoxynojirimycin as standard (IC 50 = 52.02 ± 0.36 μM). Compounds from series B and C found to be highly active however, the compounds from series D found generally less active. The structure–activity relationships demonstrated the importance of C-5 carboxamides, C-5 ethyl ester functionality, and the presence of N,S-dimethyl groups at pyrimidine ring for α-glucosidase inhibition. The docking studies demonstrated that all the active compounds have van der Waal and alkyl bonds interactions with the targeted site of the human lysosomal acid α −glucosidase. All these compounds were also tested for antioxidant potential by DPPH radical scavenging protocol that exhibited significant antioxidant effects (IC 50 = 21.4 ± 0.45 to 92.1 ± 0.38 μM) as compared to the standard butylated hydroxyanisol (IC 50 = 44.2 ± 0.36 μM). Among all, compound 13, 14 and 19 with potent α-glucosidase inhibition (IC 50 = 18.9 ± 0.72, 23.3 ± 0.45 and 21.5 ± 0.16 μM, respectively) along with excellent antioxidant potential in the range of (IC 50 = 21.4 ± 0.45 to 31.2 ± 0.23 μM) indicated their ability to use as valuable leads for the development of anti-diabetic drugs with the combined effects of antioxidants.

[Synthesis, Biological Activity and Molecular Docking Research of N-{[(4-oxo-thiochroman-3-yl)phenyl]-methyl}acetamide Derivatives As Α-Glucosidase Inhibitors].

Synthesis and Evaluation of the Α-Glucosidase Inhibitory Activity of 3-[4-(phenylsulfonamido)benzoyl]-2h-1-benzopyran-2-one Derivatives

Synthesis of Novel Β-Amino Ketones Containing a P -Aminobenzoic Acid Moiety and Evaluation of Their Antidiabetic Activities

Ultrasound-assisted synthesis of 4-thiazolidinone Schiff bases and their antioxidant, α-glucosidase, α-amylase inhibition, mode of inhibition and computational studies

Discovery of new 2-phenyl-1H-benzo[d]imidazole core-based potent α-glucosidase inhibitors: Synthesis, kinetic study, molecular docking, and in vivo anti-hyperglycemic evaluation

Design, Synthesis and Biological Evaluation of Novel (E)-2-benzylidene-n-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)hydrazine-1-carboxamide Derivatives As Α-Glucosidase Inhibitors.

Design, synthesis, biological evaluation, and docking study of chromone-based phenylhydrazone and benzoylhydrazone derivatives as antidiabetic agents targeting α‐glucosidase

Potent α-glucosidase inhibitors with benzimidazole-propionitrile hybridization; synthesis, bioassay and docking study

Synthesis of 1,2,3-benzotriazin-4(3H)-one derivatives as α-glucosidase inhibitor and their in-silico study

Novel carbazole-oxadiazole derivatives as anti-α-glucosidase and anti-α-amylase agents: Design, synthesis, molecular docking, and biological evaluation

Novel tetrahydrobenzo[b]thiophen-2-yl)urea derivatives as novel α-glucosidase inhibitors: Synthesis, kinetics study, molecular docking, and in vivo anti-hyperglycemic evaluation

Identification of 1,3,4-oxadiazolyl-containing β-carboline derivatives as novel α-glucosidase inhibitors with antidiabetic activity

Design, synthesis, in silico, and in vitro evaluation of benzylbenzimidazolone derivatives as potential drugs on α-glucosidase and glucokinase as pharmacological targets

Fluorinated indeno-quinoxaline bearing thiazole moieties as hypoglycaemic agents targeting α-amylase, and α-glucosidase: synthesis, molecular docking, and ADMET studies

Exploring the synthesis, molecular structure and biological activities of novel Bis -Schiff base derivatives: A combined theoretical and experimental approach

A Combined Experimental and Computational Study of Novel Benzotriazinone Carboxamides as Alpha-Glucosidase Inhibitors

Design of new α-glucosidase inhibitors based on the bis-4-hydroxycoumarin skeleton: Synthesis, evaluation, and in silico studies

Synthesis, biological evaluation, and molecular modelling of novel quinoxaline-isoxazole hybrid as anti-hyperglycemic

Synthesis, highly potent α-glucosidase inhibition, antioxidant and molecular docking of various novel dihydropyrimidine derivatives to treat diabetes mellitus

Preparation of Novel 3,4,5‐Triaryl‐1,2,4‐Oxadiazole Derivatives: Molecular Docking and α‐Glucosidase assessment